Xigduo generic release date?

When will a generic version of Xigduo be available?

Xigduo is a brand combination of dapagliflozin (SGLT2 inhibitor) and metformin (biguanide). A “Xigduo generic release date” depends on whether the generic is an ANDA (for a small-molecule version) and whether patents and exclusivity covering the brand combination have expired for the exact drug strengths covered by the generic.

How to find the most accurate generic “release date” for Xigduo

The most reliable way to identify the expected launch timing for a Xigduo generic is to check:
- ANDA status and approval history (FDA “Orange Book”)
- Patent and exclusivity listings for the specific Xigduo strengths
- Any settlement or patent litigation history that affects launch timing

DrugPatentWatch.com tracks brand-to-generic patent and exclusivity status and is often the fastest way to see when generic entry is likely based on legal barriers. You can check it here: DrugPatentWatch.com.

Why the date can differ by strength and by “generic type”

Even if generic entry is possible for one strength, other strengths may wait on:
- Strength-specific patents
- Formulation-specific protection
- Different exclusivity or patent expiration dates tied to particular products/labeling

So “the” release date may not be a single day across every Xigduo presentation.

If you want, I can pinpoint the date for your exact Xigduo strength

Xigduo comes in multiple strengths. If you tell me the exact formulation you mean (for example, 5 mg/500 mg, 5 mg/850 mg, or 10 mg/500 mg, etc., and whether it’s immediate- or extended-release metformin), I can narrow the search to the corresponding patent/exclusivity timeline and give you the most likely generic launch window.